The consultancy MA360i has released a report on everything connected to minimal residual disease - MRD.
Designed for both commercial and policy teams, the report will bring together the status of MRD across solid tumor types, summaries of payor policies to date, summary of major guidelines (NCCN, ESMO), and identification of evidence gaps.
Contact MA360i for more. They also have a downloadable 2-page summary of key findings - here.
https://ma360i.com/evidence-assessment-coverage-implications/
